A Multicenter Prospective Registration Study of Myasthenic Crisis in China

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

This study is a multicenter, prospective, observational research. It will register the basic demographic information, medical history characteristics, clinical features, auxiliary examinations, treatment, outcomes of tracheal intubation/ventilator related events, and clinical outcomes of Myasthenic Crisis patients. The objectives including: 1. Obtain epidemiological data of MC in China; 2. Establish a standardized registration system for MC patients in China; 3. Explore the epidemiology, clinical characteristics, serological characteristics, clinical characteristics of MC, predisposing and predictive factors, extubation process/time, weaning/extubation outcome and predictors of clinical outcome in Chinese MC patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• clinical history and signs of fluctuating weakness and fatigability;

• seropositivity forAChR/MuSKantibodies;

• If negative or the tested antibodies, positive repetitive nerve stimulation(RNS) at low frequency(2-5Hz) is required;

• Crisis: a serious, life-threatening, rapid worsening of MG requiring intubation or noninvasive ventilation to avoid intubation.

• Impending crisis: rapid clinical worsening of MG that, in the opinion of the treating physician, could lead to crisis in the short term (days to weeks) with blood gases suggest hypoxia (oxygen saturation \<95%) or elevated carbon dioxide (paco2\>50mmHg).

Locations
Other Locations
China
Huashan Hospital Fudan University
RECRUITING
Shanghai
Contact Information
Primary
Xiao Huan, MD
hx941223@163.com
+8618351973910
Backup
Susan Luo, MD;PHD
SusanRo_36@hotmail.com
Time Frame
Start Date: 2020-10-01
Estimated Completion Date: 2026-09-30
Participants
Target number of participants: 300
Treatments
Myasthenic Crisis Cohort
Related Therapeutic Areas
Sponsors
Leads: Huashan Hospital

This content was sourced from clinicaltrials.gov